abstract |
The present disclosure provides humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. Experimental results are detailed for a few antibodies, derived from mouse antibodies. The mouse antibody with the internal name mab729 [ having as CDRs VH1:GLTFRDFA; VH2:ISSGGFYT, VH3:VRRAYRYDGTGDYSALDY, VLl:QDIGPS, VL2:ATS; VL3:LQFASSPLT ] is further humanized (internal name mAB 650_H 1L1). Said antibody inhibits CCR7 receptor internalization, as shown by experimental results. |